FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/03/2023
Back to search
Official data from USPTO
BILIX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
01/03/2023
Classification
Registered
Trademark type
Word
Nice classes
5, 42
Filing date
11/11/2020
Registration date
09/06/2022
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/06/2022
Last transaction
09/06/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
KR
Examiner
LAM, HAI-LY HUYNH
Law office
N10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Bilix Co., Ltd.
Representatives
James R Menker Holley & Menker, PA
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for neurological disease; pharmaceutical preparations for inflammatory diseases; pharmaceutical preparations for ocular and intraocular surgery; pharmaceutical preparations for rare autoimmune diseases in the nature of autoimmune lymphoproliferative syndromelupusmultiple sclerosis; pharmaceutical products for the treatment of rare autoimmune diseases and disorders; pharmaceutical products for the prevention and treatment of rare genetic diseases affecting red blood cells; medicated ointments for treating dermatological conditions; antibiotic ointments; mentholated ointment for medical use; anti-inflammatory ointments; chemical reagents for purposes of medical diagnosis; diagnostic preparations for diagnosing inflammatory diseases; diagnostic radiopharmaceutical preparations; pharmaceutical and biological preparations for use in diagnosisfor use as ultrasound and x-ray contrast reagents; antibiotics; anti-inflammatory preparations; anti-cancer preparations; biological preparations for the treatment of cancer; cardiovascular pharmaceutical preparations; dermatological pharmaceutical products; diagnostic preparations for medical or veterinary purposes; genetic identity tests comprised of reagents for medical purposes; human vaccine preparations; medicines for dental purposes; medicines for intestinal disorders; ophthalmic preparations; pharmaceutical agents affecting digestive organs; pharmaceutical agents affecting metabolism; pharmaceutical agents affecting peripheral nervous system; pharmaceutical agents affecting sensory organs; pharmaceutical preparations acting on the central nervous system; pharmaceutical agents for epidermis; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for peripheral nervous system; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of musculo-skeletal disorders; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for treating skin disorders; pharmaceutical products for the treatment of cancer; pharmaceutical products for the treatment of infectious diseases; pharmaceutical products for the treatment of viral diseases; pharmaceutical products for treating respiratory diseases; pharmaceuticals for the treatment of erectile dysfunction; preparations for the treatment of asthma; tumor suppressing agents; vaccines; immunoassay reagents for medical use
Class 42
Pharmaceutical research services; drug discovery services; medical research; pharmaceutical product evaluation; scientific investigations for medical purposes; scientific research for medical purposes in the area of cancerous diseases; development of pharmaceutical preparations and medicines; consulting on the testinginspection and research of medical products for quality control purposes; providing information on the testinginspection and research of medical products for quality control purposes; industrial research in the fields of medicinehealth and pharmacology; engineering services in the medical technology field
Publications
History of USPTO decisions and trademark events.
41 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/09/2022
FIMP
FINAL DISPOSITION PROCESSED
12/09/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/06/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/06/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
09/06/2022
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
07/11/2022
GPNX
NOTIFICATION PROCESSED BY IB
07/05/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/22/2022
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
06/22/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/21/2022
PUBO
PUBLISHED FOR OPPOSITION
06/21/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
06/08/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
06/08/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/01/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/13/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
04/28/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/28/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
04/28/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/28/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/31/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/31/2022
ALIE
ASSIGNED TO LIE
03/31/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/29/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/29/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/29/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/29/2021
GNRT
NON-FINAL ACTION E-MAILED
10/29/2021
CNRT
NON-FINAL ACTION WRITTEN
10/29/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/30/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/30/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/30/2021
RFNT
REFUSAL PROCESSED BY IB
05/17/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/26/2021
RFRR
REFUSAL PROCESSED BY MPU
04/26/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/23/2021
CNRT
NON-FINAL ACTION WRITTEN
04/22/2021
DOCK
ASSIGNED TO EXAMINER
04/21/2021
MAFR
APPLICATION FILING RECEIPT MAILED
01/26/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/22/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/21/2021
Continuous trademark protection
Get notified about every new filing that threatens BILIX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.